Biological monitoring is an essential part of the management of HIV infection. The aim of this study was to assess serum
amylase activity during follow-up of children living with HIV-1 (CLHIV-1) at the Charles de Gaulle Pediatric University
Hospital (CHUP-CDG). This was a descriptive and analytical cross-sectional study, with retrospective data collection from
January 1, 2020 to December 31, 2022. Patients under 15 years of age who were being monitored for HIV-1 at CHUP-CDG
and who had undergone a serum amylase assay during the study period were included. A total of 746 patients have been
included, with a M/F sex ratio of 0.91 and a mean age of 8.52±4.08 years. Among CLHIV-1, 88.05% had a TCD4 lymphocyte
count 500/mm3 and 60.32% an undetectable plasma viral load (PVL). The incidence of hyperamylasemia in the study
population was 57.64%. Hyperamylasemia was significantly more frequent in children aged 0-2 years (p

Hyperamylasemia Serum Amylase Activity Children HIV-1 Burkina Faso